Skip to main content
. 2021 Feb 20;13(4):892. doi: 10.3390/cancers13040892

Figure 2.

Figure 2

Comparison of BRAF, RAS, TERT promoter, and TP53 mutations: (A) papillary thyroid carcinoma (PTC) from The Cancer Genome Atlas (TCGA); (B) aggressive variants of PTC in current study; (C) poorly differentiated carcinoma (PDTC) and (D) anaplastic thyroid carcinoma (ATC) from the Memorial Sloan Kettering Cancer Center (MSKCC) group; (E) advanced PTCs from other studies [17,19,20,21].